Skip to search formSkip to main contentSkip to account menu

VePesid-Ifosfamide-Platinol Regimen

Known as: VP16-Ifosfamide-Platinol Regimen, Etoposide-Ifosfamide-Cisplatin Regimen, VIP 
A regimen consisting of etoposide, ifosfamide and cisplatin used for the treatment of advanced-stage germ cell gonadal cancers.
National Institutes of Health

Related topics

Related topics

5 relations
CisplatinEtoposideIfosfamideTesticular malignant germ cell tumor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95
Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission… 
Highly Cited
2008
Highly Cited
2008
A randomized trial comparing compression, perclose proglide™ and Angio‐Seal VIP™ for arterial closure following percutaneous coronary intervention: The cap trial
Objective: This prospective randomized trial compared the Angio‐Seal VIP™ with Perclose Proglide™ and to manual compression with… 
Highly Cited
2003
Highly Cited
2003
Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors
Various staging systems have been proposed for disseminated germ cell neoplasms. The Indiana University staging system was based… 
Highly Cited
2003
Highly Cited
2003
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an…
PURPOSE Patients with disseminated germ cell cancer and poor prognosis (International Germ Cell Cancer Collaborative Group… 
Highly Cited
2001
Highly Cited
2001
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma
Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents… 
Highly Cited
1999
Highly Cited
1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
PURPOSE To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose… 
Highly Cited
1998
Highly Cited
1998
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology…
PURPOSE To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide… 
Highly Cited
1997
Highly Cited
1997
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
PURPOSE A treatment program that included high-dose carboplatin, etoposide, and cyclophosphamide (CEC) followed by autologous… 
Highly Cited
1993
Highly Cited
1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte‐colony stimulating factor accelerate both neutrophil and platelet recovery after high‐dose VP16, ifosfamide and cisplatin
Summary. We report on the chemotherapy plus granulocyte colony‐stimulating factor (G‐CSF) induced mobilization of peripheral… 
Highly Cited
1988
Highly Cited
1988
Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
STUDY OBJECTIVE To determine the efficacy of the addition of ifosfamide to cisplatin plus etoposide (VIP), or vinblastine (VeIP… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)